Phase II clinical trial of the first-line Stop-and-Go modified FOLFOX6 and bevacizmab for patients with unresectable/recurrent colorectal cancer

Interventions: After 8 cycles of modified FOLFOX 6 with bevacizmab, patients receive sLV5FU2 with bevacizumab (until 8 cycles are completed or disease progression). And then, patients receive modified FOLFOX6 with bevacizmab (until 8 cycles are completed or disease progression.) Primary outcome(s): Response rate Study Design: Single arm Non-randomized